COMMUNIQUÉS West-GlobeNewswire

-
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
15/02/2024 -
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
15/02/2024 -
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
15/02/2024 -
Theratechnologies complète le recrutement des six premières patientes de l’essai clinique de phase I mis à jour sur le sudocétaxel zendusortide dans le traitement du cancer de l’ovaire avancé
15/02/2024 -
Avicanna Announces New Research Collaboration with a Multi-national European-based Pharmaceutical Company
15/02/2024 -
Bitech Technologies Completes Due Diligence on BESS Projects to Prepare for a Business Combination
15/02/2024 -
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
15/02/2024 -
Sotera Health Announces Fourth-Quarter and Full-Year 2023 Earnings Release Date
15/02/2024 -
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
15/02/2024 -
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
15/02/2024 -
Widmer Brothers Brewing’s Beloved White Gold Hazy Lager Returns
15/02/2024 -
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
15/02/2024 -
Hydreight Founder and CEO, Shane Madden, Joins Founding Member Board of the American IV Association
15/02/2024 -
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
15/02/2024 -
XORTX Raises $2.5 Million Under Prospectus Supplement and Concurrent Private Placement for the Offering of Units
15/02/2024 -
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
15/02/2024 -
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
15/02/2024 -
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
15/02/2024 -
Tricha Shivas Promoted to Chief of Staff and Strategy at Foundation for Sarcoidosis Research
15/02/2024
Pages